Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Ref Type | Journal Article | ||||||||||||
| PMID | (26689995) | ||||||||||||
| Authors | Umelo I, Noeparast A, Chen G, Renard M, Geers C, Vansteenkiste J, Giron P, De Wever O, Teugels E, De Grève J | ||||||||||||
| Title | Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer. | ||||||||||||
|
|||||||||||||
| URL | |||||||||||||
| Abstract Text | Somatic mutations found within the tyrosine kinase domain (TKD) of the human epidermal growth factor (HER) family of receptors have been implicated in the development and progression of non-small cell lung cancer (NSCLC). However, no conclusive reports have described pathogenic mutations in kinase-impaired HER3. Here, we report a case of an advanced chemotherapy-resistant NSCLC, harboring a novel HER3(V855A) somatic mutation homologous to the EGFR(L858R)activating mutation. Co-expression of HER3(V855A) and wild-type HER2 enhances ligand-induced transformation of murine and human cell lines, while HER-targeted inhibitors potently suppress mutant HER3 activity. Consistent with these observations, in silico computational modeling predicts that mutant V855A alters the kinase domain and c-terminal end of the HER3 protein. Taken together, these findings provide a basis for the clinical exploration of targeted therapies in HER3 mutant NSCLC and by extrapolation, in other cancers that more frequently carry somatic HER3 mutations. | ||||||||||||
| Molecular Profile | Treatment Approach |
|---|---|
| ERBB3 S846I | Pertuzumab |
| ERBB3 V104L | Pertuzumab |
| ERBB3 A232V | Pertuzumab |
| ERBB3 act mut | Pertuzumab |
| ERBB3 T389K | Pertuzumab |
| ERBB3 P262H | Pertuzumab |
| ERBB3 E928G | Pertuzumab |
| ERBB3 Q809R | Pertuzumab |
| Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
|---|
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|
| Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
|---|---|---|---|---|---|
| ERBB3 | V855A | missense | gain of function | ERBB3 (HER3) V855A lies within the activation loop of the Erbb3 (Her3) protein (PMID: 26689995). V855A confers a gain of function to Erbb3 (Her3), as indicated by increased NRG1-beta induced cell growth in the presence of wild-type ERBB2 (HER2), increased interaction with ERBB2 (HER2), and increased ERBB2 (HER2) trans-phosphorylation in cell culture (PMID: 26689995). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|